公开(公告)号：DK0749429T3

公开(公告)日：2000-01-10

申请号：DK95912197

申请日：1995-03-03

Applicant: HOECHST AG

Inventor： SCHWAB WILFRIED ,  ANAGNOSTOPULOS HIRISTO ,  BARTLETT ROBERT RYDER ,  SCHLEYERBACH RUDOLF ,  WEITHMANN KLAUS ULRICH

IPC: A61K31/41 ,  A61K31/42 ,  A61K31/423 ,  A61K31/495 ,  A61K31/496 ,  A61K31/535 ,  A61K31/5377 ,  A61P11/00 ,  A61P29/00 ,  A61P37/00 ,  C07C205/51 ,  C07D261/04 ,  C07D261/08 ,  C07D261/18 ,  C07D261/20 ,  C07D263/30 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07F9/653

Abstract: PCT No. PCT/EP95/00784 Sec. 371 Date Nov. 19, 1996 Sec. 102(e) Date Nov. 19, 1996 PCT Filed Mar. 3, 1995 PCT Pub. No. WO95/24397 PCT Pub. Date Sep. 14, 1995A compound having the formula (I), a physiologically tolerable salt of the compound having the formula (I) and/or a steroisomeric form of the compound having the formula (I), in which one residue R1 or R2 stands for the formula (II), are suitable for preparing medicaments for the therapy of inflammations, asthma, rheumatoid diseases and auto-immune diseases.

公开(公告)号：CA2237099A1

公开(公告)日：1998-11-09

申请号：CA2237099

申请日：1998-05-07

Applicant: HOECHST AG

Inventor： THORWART WERNER ,  HAASE BURKHARD ,  SCHUDOK MANFRED ,  SCHWAB WILFRIED

IPC: C07D307/54 ,  A61K31/18 ,  A61K31/195 ,  A61K31/245 ,  A61K31/275 ,  A61K31/34 ,  A61K31/36 ,  A61K31/38 ,  A61K31/381 ,  A61K31/395 ,  A61K31/396 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/405 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/421 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4433 ,  A61K31/445 ,  A61K31/454 ,  A61K31/63 ,  A61K31/66 ,  A61K31/665 ,  A61K31/67 ,  A61P9/00 ,  A61P9/10 ,  A61P19/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07C311/16 ,  C07C311/19 ,  C07C311/29 ,  C07C311/37 ,  C07C311/42 ,  C07C311/44 ,  C07C317/48 ,  C07C323/51 ,  C07C323/58 ,  C07C323/59 ,  C07C381/10 ,  C07D203/06 ,  C07D203/24 ,  C07D205/04 ,  C07D207/12 ,  C07D207/16 ,  C07D207/48 ,  C07D209/08 ,  C07D209/10 ,  C07D209/18 ,  C07D209/20 ,  C07D211/96 ,  C07D213/42 ,  C07D213/55 ,  C07D213/75 ,  C07D233/20 ,  C07D233/54 ,  C07D233/64 ,  C07D235/16 ,  C07D249/06 ,  C07D263/04 ,  C07D277/16 ,  C07D277/20 ,  C07D277/36 ,  C07D295/08 ,  C07D307/58 ,  C07D317/60 ,  C07D333/22 ,  C07D333/24 ,  C07D333/34 ,  C07D333/60 ,  C07D401/12 ,  C07D403/12 ,  C07D409/04 ,  C07D413/04 ,  C07F9/30 ,  C07D261/08 ,  C07D295/155 ,  A61K31/33 ,  C07C311/64

Abstract: Compounds of the formula I (see fig. I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases in involved.

公开(公告)号：TR9800849T2

公开(公告)日：1998-07-21

申请号：TR9800849

申请日：1996-11-04

Applicant: HOECHST AG

Inventor： THORWART WERNER ,  SCHWAB WILFRIED ,  SCHUDOK MANFRED ,  HAASE BURKHARD ,  BARTNIK ECKART ,  WEITHMANN KLAUS-ULRICH

IPC: A61K31/00 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/4725 ,  A61P43/00 ,  C07D209/42 ,  C07D217/26 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D491/04 ,  C07D491/056 ,  A61K31/40

CPC classification number: C07D405/12 ,  C07D209/42 ,  C07D217/26 ,  C07D471/04 ,  C07D491/04

公开(公告)号：FI963508A0

公开(公告)日：1996-09-06

申请号：FI963508

申请日：1996-09-06

Applicant: HOECHST AG

Inventor： SCHWAB WILFRIED ,  ANAGNOSTOPULOS HIRISTO ,  BARTLETT ROBERT RYDER ,  SCHLEYERBACH RUDOLF ,  WEITHMANN KLAUS ULRICH

IPC: A61K31/41 ,  A61K31/42 ,  A61K31/423 ,  A61K31/495 ,  A61K31/496 ,  A61K31/535 ,  A61K31/5377 ,  A61P11/00 ,  A61P29/00 ,  A61P37/00 ,  C07C205/51 ,  C07D261/04 ,  C07D261/08 ,  C07D261/18 ,  C07D261/20 ,  C07D263/30 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07F9/653 ,  C07D

Abstract: PCT No. PCT/EP95/00784 Sec. 371 Date Nov. 19, 1996 Sec. 102(e) Date Nov. 19, 1996 PCT Filed Mar. 3, 1995 PCT Pub. No. WO95/24397 PCT Pub. Date Sep. 14, 1995A compound having the formula (I), a physiologically tolerable salt of the compound having the formula (I) and/or a steroisomeric form of the compound having the formula (I), in which one residue R1 or R2 stands for the formula (II), are suitable for preparing medicaments for the therapy of inflammations, asthma, rheumatoid diseases and auto-immune diseases.

公开(公告)号：AU1948195A

公开(公告)日：1995-09-25

申请号：AU1948195

申请日：1995-03-03

Applicant: HOECHST AG

Inventor： SCHWAB WILFRIED ,  ANAGNOSTOPULOS HIRISTO ,  BARTLETT ROBERT RYDER ,  SCHLEYERBACH RUDOLF ,  WEITHMANN KLAUS ULRICH

IPC: A61K31/41 ,  A61K31/42 ,  A61K31/423 ,  A61K31/495 ,  A61K31/496 ,  A61K31/535 ,  A61K31/5377 ,  A61P11/00 ,  A61P29/00 ,  A61P37/00 ,  C07C205/51 ,  C07D261/04 ,  C07D261/08 ,  C07D261/18 ,  C07D261/20 ,  C07D263/30 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07F9/653

Abstract: PCT No. PCT/EP95/00784 Sec. 371 Date Nov. 19, 1996 Sec. 102(e) Date Nov. 19, 1996 PCT Filed Mar. 3, 1995 PCT Pub. No. WO95/24397 PCT Pub. Date Sep. 14, 1995A compound having the formula (I), a physiologically tolerable salt of the compound having the formula (I) and/or a steroisomeric form of the compound having the formula (I), in which one residue R1 or R2 stands for the formula (II), are suitable for preparing medicaments for the therapy of inflammations, asthma, rheumatoid diseases and auto-immune diseases.

公开(公告)号：DK165836B

公开(公告)日：1993-01-25

申请号：DK224384

申请日：1984-05-04

Applicant: HOECHST AG

Inventor： KIRRSTETTER REINER ,  DUERCKHEIMER WALTER ,  LATTRELL RUDOLF ,  SCHWAB WILFRIED

IPC: A61K31/425 ,  A61K31/545 ,  C07D20060101 ,  C07D501/00 ,  C07D501/04 ,  C07D501/06 ,  C07D501/38 ,  C07D501/46 ,  C07D501/56 ,  C07D501/57 ,  C07D519/00

Abstract: Process for the preparation of cephem compounds of the formula wherein R is optionally substituted aminothiazolyl or amino-1,2,4-thiadiazolyl, A is optionally substituted pyridinium, R1 is hydrogen or methoxy and R2 are special aliphatic substituents, by a nucleophilic replacement in the substituent in 3-position in the presence of tri-C1C4-alkyl iodosilane.

公开(公告)号：NO911432A

公开(公告)日：1991-10-14

申请号：NO911432

申请日：1991-04-11

Applicant: HOECHST AG

Inventor： SCHWAB WILFRIED ,  ANAGNOSTOPULOS HIRISTO ,  PORSCHE-WIEBKING ELENA ,  GROME JOHN

IPC: A61K31/415 ,  A61K31/44 ,  A61K31/445 ,  A61K31/675 ,  A61P9/10 ,  A61P25/08 ,  A61P25/18 ,  A61P25/28 ,  C07D261/04 ,  C07D261/08 ,  C07D261/12 ,  C07D261/18 ,  C07D413/04 ,  C07D413/06 ,  C07F9/653

CPC classification number: C07D413/04 ,  C07D261/04 ,  C07D261/08 ,  C07D261/18 ,  C07F9/653

公开(公告)号：AU608076B2

公开(公告)日：1991-03-21

申请号：AU2419588

申请日：1988-10-25

Applicant: HOECHST AG

Inventor： SCHWAB WILFRIED ,  BARTLETT ROBERT RYDER ,  GEBERT ULRICH ,  SCHORLEMMER HANS ULRICH ,  DICKNEITE GERHARD ,  SEDLACEK HANS HARALD

IPC: A61K31/675 ,  A61K39/39 ,  A61P35/00 ,  A61P37/00 ,  C07F9/40 ,  C07F9/547 ,  C07F9/653 ,  C07F9/6574 ,  C07F9/65 ,  A61K31/685

Abstract: The medicine contains or consists of at least one compound of the formula I and/or optionally one of its physiologically tolerated salts, where the compounds of the formula I can optionally be in the form of pure stereoisomers or mixtures thereof; formula I is: in which R = organic radical or halogen A = C,C single or C,C double bond, n = 0, 1 or 2 and X and Y = alkyl radical or = -OR or -NR R with R , R = H or optionally substituted aliphatic radical. The medicines are suitable for the prophylaxis and/or treatment of disorders of the immune system.

公开(公告)号：FI82055B

公开(公告)日：1990-09-28

申请号：FI841764

申请日：1984-05-03

Applicant: HOECHST AG

Inventor： SCHWAB WILFRIED ,  DUERCKHEIMER WALTER ,  KIRRSTETTER REINER ,  LATTRELL RUDOLF

IPC: C07D501/04 ,  A61K31/425 ,  A61K31/545 ,  C07D20060101 ,  C07D501/00 ,  C07D501/06 ,  C07D501/38 ,  C07D501/46 ,  C07D501/56 ,  C07D501/57

Abstract: Process for the preparation of cephem compounds of the formula

公开(公告)号：FI884911A0

公开(公告)日：1988-10-24

申请号：FI884911

申请日：1988-10-24

Applicant: HOECHST AG

Inventor： SCHWAB WILFRIED ,  BARTLETT ROBERT RYDER ,  GEBERT ULRICH ,  SCHORLEMMER HANS ULRICH ,  DICKNEITE GERHARD ,  SEDLACEK HANS HARALD

IPC: A61K31/675 ,  A61K39/39 ,  A61P35/00 ,  A61P37/00 ,  C07F9/40 ,  C07F9/547 ,  C07F9/653 ,  C07F9/6574 ,  C07F

Abstract: The medicine contains or consists of at least one compound of the formula I and/or optionally one of its physiologically tolerated salts, where the compounds of the formula I can optionally be in the form of pure stereoisomers or mixtures thereof; formula I is: in which R = organic radical or halogen A = C,C single or C,C double bond, n = 0, 1 or 2 and X and Y = alkyl radical or = -OR or -NR R with R , R = H or optionally substituted aliphatic radical. The medicines are suitable for the prophylaxis and/or treatment of disorders of the immune system.